Curaleaf Q2 FY26 net income turns to profit at USD 12.5 million; revenue rises 10% to USD 340 million
Operational updates
The company expanded its Florida retail footprint to 73 dispensaries in the quarter, completed the buyout of the remaining 45% of Four20 Pharma, and applied to register U.S. medical sites with the DEA.
Margins, cash and debt
GAAP gross margin widened 0.7 percentage points to 50%, while non-GAAP adjusted EBITDA rose 3.3% to USD 70.1 million, cutting margin 1.2 points to 20.6%.
Cash totaled USD 107 million at quarter-end; outstanding debt was USD 611.5 million, and six-month free cash flow from continuing operations was USD 17.4 million (non-GAAP).
Q2 revenue and profit improve
Curaleaf posted Q2 2026 net revenue of USD 340 million, up 10% year over year; international revenue climbed 26% to USD 51 million.
Net income from continuing operations swung to a GAAP profit of , versus a prior-year loss; diluted EPS from continuing operations was .
